Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|61|4|737-739

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.61, Iss.4, 2014-04, pp. : 737-739

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Successful Treatment of Autoimmune Hemolytic Anemia Associated with Multicentric Castleman Disease by Anti-Interleukin-6 Receptor Antibody (Tocilizumab) Therapy

By  

Acta Haematologica, Vol. 126, Iss. 3, 2011-07 ,pp. : 147-150

Karger

Access to resources Recommend Favorite

Sustained Partial Remission of Metastatic Pancreatic Cancer Following Systemic Chemotherapy with Gemcitabine and Oxaliplatin plus Adjunctive Treatment with Mistletoe Extract

By  

Oncology Research and Treatment, Vol. 33, Iss. 11, 2010-10 ,pp. : 617-619

Karger

Access to resources Recommend Favorite

AIDS, Multicentric Castleman's Disease, and Plasmablastic Leukemia: Report of a Long-Term Survival

By Horster S.  

Infection, Vol. 32, Iss. 5, 2004-10 ,pp. : 296-298

Springer Publishing Company

Access to resources Recommend Favorite

KSHV‐associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 2, 2015-07 ,pp. : 251-261

John Wiley & Sons Inc

Access to resources Recommend Favorite

Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis—TAFRO syndrome

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 1091-1092

John Wiley & Sons Inc

Access to resources Recommend Favorite